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Key Points
1. Liver transplantation is currently offered as a therapeu-
tic option for patients with a wide range of end-stage liver
diseases.
2. Conventional wisdom suggests that patients who
receive a liver transplant have a greater expected lifetime
when compared to comparable candidates on the waiting
list.
3. The model for end-stage liver disease (MELD) scoring
system is an excellent predictor of mortality on the waiting
list and also predicts mortality after liver transplantation.
4. The combination of waiting list mortality risk and
posttransplant mortality risk assessed by MELD and other
factors can be used to estimate whether candidates are
likely to derive a survival benefit from a liver transplant.
(Liver Transpl 2004;10:S69–S73.)
In an ideal world, every patient with liver diseasewhose predicted lifetime with a transplant is longer
than his or her lifetime without a transplant would be
able to receive an organ transplant at an optimal and
timely point in the course of their disease and no wait-
ing list deaths would occur. Transplants would not be
performed in circumstances in which the nontransplant
option was associated with a longer lifetime, and this
statement would hold true for patients throughout the
disease severity spectrum.
Of course, we are unlikely to inhabit such a world
anytime soon. Donor organs are available in small num-
bers relative to the pool of candidates and our ability to
predict the future lifetimes of individual patients is lim-
ited. Liver transplantation is currently offered as a ther-
apeutic option for patients with a wide range of end-
stage liver diseases whose outcome is predicted to be
fatal, usually at a point when the candidate is still
expected to live long enough to survive the uncertain
wait for a donor organ. Listing criteria for liver trans-
plantation are currently very broad and delisting criteria
have never been promulgated or placed into policy.
The model for end-stage liver disease (MELD) scor-
ing system has emerged as an excellent predictor of
mortality on the waiting list1,2 and also predicts mortal-
ity after liver transplantation.3 The combination of
waiting list mortality risk and posttransplant mortality
risk assessed by MELD and other factors can be used to
estimate whether candidates are likely to derive a sur-
vival benefit from a liver transplant.4–6 In this essay, I
discuss transplant decision-making approaches for liver
transplant candidates, focusing especially on patients at
the ends of the risk spectrum.
Predictions of Waiting List Mortality
The development of MELD marked an important
milestone in our ability to predict the prognosis of
patients with chronic liver disease.7,8 Derived from a
trio of simple, reproducible, and objective laboratory
parameters (serum bilirubin, prothrombin time inter-
national normalized ratio, and serum creatinine),
MELD provides robust estimates of mortality risk
across a broad range of patients.8 The initial elaboration
of the MELD score was based on a cohort of patients
undergoing transjugular intrahepatic portosystemic
shunt procedures for portal hypertension.7 Later
reports showed that MELD was also predictive of liver
patients generally, as well as those selected as potential
liver transplant candidates.2,8 A modification of MELD
was developed to account for the needs of pediatric liver
transplant candidates (the pediatric end-stage liver dis-
ease scoring system), incorporating information on
serum albumin and growth failure.8,9 In addition to the
value of MELD per se as a predictor of mortality, the
rate of change in MELD has also been shown to be
independently associated with mortality risk in wait-
listed candidates.10
Once a patient has been placed on the waiting list, it
is of interest to know the likely direction and magnitude
of subsequent changes in MELD score (and the associ-
ated risk). We studied 18,361 candidates waitlisted
between April 1, 2002 and March 31, 2004, and ana-
lyzed 60,391 MELD scores while active on the waitlist
Abbreviations: MELD, model for end-stage liver disease.
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through March 31, 2004. Change in the MELD score
at time of next reported score (delta MELD) was calcu-
lated by category of MELD, and by the time between
the 2 MELD scores. Figure 1 shows that for patients
with low MELD scores, progression tends to be mod-
estly upward, but not at a particularly rapid pace. In
contrast, patients with high MELD scores tend, on
average, to have declining scores.
The mortality risk on the waiting list while a patient
has any given MELD score can be reliably estimated
(Fig. 2). In addition to MELD, other parameters have
been examined to determine whether they add measur-
ably to the assessment of waiting list mortality risk.
These factors include additional laboratory values such
as serum albumin, as well as more subjective variables
such as a history of variceal hemorrhage, ascites, or
portosystemic encephalopathy. In an expanded mortal-
ity model, Dykstra et al.11 found that while the listed
covariates were significant independent predictors,
their contribution to the goodness-of-fit of the model
was modest when compared to the original components
of MELD. Ruf et al.12 found that the goodness-of-fit of
the mortality prediction using MELD was improved by
the addition of serum sodium as an objective surrogate
for ascites.
Predictions of Posttransplant Mortality
Some of the components of MELD were found to pre-
dict posttransplant mortality almost 20 years ago.13,14
In particular, pretransplant renal dysfunction has long
been recognized as an important risk factor for post-
transplant death.14 More recently, the other compo-
nents of the MELD score have also been shown to be
predictive of posttransplant mortality. While unad-
justed waiting list mortality rates cover a 300-fold range
from low to high MELD scores, the range of corre-
sponding posttransplant mortality rates is about 2-fold
Figure 1. Box plots of change in MELD score compared to current MELD score, by MELD score.
Figure 2. Box plots of mortality risk on the waiting list, by MELD score.
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(Table 1). More completely specified models of post-
transplant mortality are being constructed using the
values of variables known at the time of transplantation.
Covariates that are significant predictors of posttrans-
plant mortality include age, race, diagnosis, height, and
pretransplant serum creatinine; history of prior liver
transplant and primary nonfunction of prior liver trans-
plant; history of variceal bleeding, ascites, portal vein
thrombosis, and insulin-dependent diabetes mellitus;
and the need for pretransplant inotropic support, life
support, and intensive care unit or hospital care.
Combining Waiting List Mortality and
Posttransplant Mortality Risk to Determine
Transplant Survival Benefit
From the viewpoint of a liver transplant candidate, a
major question is whether their expected lifetime with a
transplant is longer than their expected lifetime without
the transplant. Unfortunately, our ability to accurately
gauge total lifetimes is quite limited, so instead we rely
upon estimates of shorter-term survival. For example, if
a patient has a predicted 1-year survival rate of 60%
without a transplant and 70% with a transplant, we
would say that there is evidence of a net transplant
survival benefit. Even an equal survival percentage at 1
year may be associated with a survival benefit if the
shapes of the 2 survival curves are different. In this case,
one can calculate the area under the 2 survival curves
and generate a statistic that represents the difference
between the expected number of days lived during a
given interval of time with or without a transplant.
Defining “Too Well”
From a survival perspective, a candidate is considered
too well to undergo liver transplantation if his or her
expected lifetime is greater in the absence of a trans-
plant. Of course, this definition does not incorporate
measures of the patient’s quality of life or burden of
disease, each of which might weigh heavily on an indi-
vidual’s desire to go ahead with a surgical procedure
that might actually shorten their life. In practical terms,
we have examined the relative mortality risk after liver
transplantation compared to the risk of death on the
waiting list, given an equivalent time since placement
on the waiting list and comparable risk of pretransplant
death (e.g., MELD score). Adjusted relative mortality
risk is significantly higher for transplanted patients than
for waitlisted patients when the MELD score is less than
15, as assessed during 1-year posttransplant follow-up.6
Given underlying chronic liver disease, however, it is
likely that the risk of death will increase over time in the
absence of a transplant. If the MELD score rises to
greater than 15, there is no longer a significantly higher
risk of death with the transplant and the patient would
no longer be considered too well.
Defining “Too Sick”
It is considerably more difficult to identify patients who
are too sick for a liver transplant, rendering a transplant
futile. Three conceptual bases for a determination of
transplant futility may be discussed. The 1st examines
the relative mortality risk of the transplant vs. contin-
ued residence on the waiting list, a measure of individ-
ual relative transplant survival benefit. Patients with
MELD scores of 18 and higher derive significant trans-
plant survival benefit, and the magnitude of benefit
increases with the score. However, candidates at very
high MELD scores are more likely to be placed on
inactive status at any given time when compared to
candidates who have lower MELD scores (Fig. 3).
Comparisons of the relative mortality risk for trans-
planted patients and waitlisted candidates at the very
high end of the MELD score spectrum may tend to
overestimate the benefit of transplantation because
selection bias in the transplanted group resulting from
appropriate physician judgment in clinical practice
enriches the waitlisted group for nonsurvivors and the
recipient group for survivors. Nonetheless, the mea-
sured benefit of transplantation for very sick candidates
is unlikely to be nullified by this methodological issue.
Second, the current MELD-based allocation policy
caps the score at 40. Thus, patients whose calculated
uncapped score is higher than 40 are aggregated with
those whose calculated score exactly equals 40. Exami-
nation of the subgroup of candidates with MELD
scores higher than 40 has revealed that such scores are
Table 1. Unadjusted Liver Waiting List and Transplant
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not associated with a diminished transplant benefit
when compared to those whose scores are exactly 40.
Third, some patients with a transplant survival ben-
efit based on relative waitlist and posttransplant mortal-
ity estimates may nonetheless have an absolute post-
transplant survival rate that is extremely low. For
example, is a 1-year posttransplant survival rate of 30%
unacceptable, even if it represents a much better sur-
vival prospect for a patient than in the absence of a
transplant? This important societal question, with far-
reaching consequences for the transplant community,
was discussed at a conference on the MELD allocation
system held in December 2003.15 At that meeting,
there was consensus that a minimum acceptable pre-
dicted absolute posttransplant survival was needed,
although the precise method for determining this level
was not able to be elaborated.
Summary
Liver transplantation has evolved to the point where the
survival benefit of the procedure can now be estimated.
The MELD scoring system allows us to estimate pre-
transplant mortality risk with remarkable precision and
provides a good 1st approximation for posttransplant
mortality risk. Comparisons of the relative mortality
risks on the waiting list and after transplant allow us to
determine whether and to what degree patients are well
served by undergoing liver transplantation in terms of
survival. Additional ongoing work on models of post-
transplant mortality risk will result in more accurate
measurements of this side of the equation. These
advancements will ultimately improve our ability to
allocate organs in a fair and equitable manner and coun-
sel potential liver transplant candidates.
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